Rosen Quoted on New Safety Threats with Approved Drugs

09 May 2017 Modern Healthcare News
Partner David Rosen was quoted in a Modern Healthcare article, “New Safety Threats Identified in One-Third of Drugs Post-Approval,” covering why these statistics make sense, and covering FDA user fees as they relate to the issue.

Rosen explained he doesn’t think “the user fee time deadlines really have an impact [on the issue]; it doesn’t mean that the FDA is putting out drugs that are less safe. The FDA takes safety very seriously and does the best job it can in making sure labels show the proper risk and benefits and are updated.”

Related Services

Insights

Bad Holiday Season News! Estimates of an increase of Cyberattacks 20%!
13 December 2019
Internet, IT & e-Discovery Blog
Driving the Future of Automotive Technology
12 December 2019
Manufacturing Industry Advisor
Massachusetts Governor Proposes Facility Fee Ban
12 December 2019
Health Care Law Today
American Rule Prevails; PTO May Not Collect In-House Attorneys' Fees as "Expenses"
12 December 2019
IP Litigation Current
ACCC 46th Annual Meeting & Cancer Center Business Summit
04-05 March 2020
Washington, D.C.
Foley/Deloitte Compliance and Privacy Officer Roundtable
27 February 2020
Boston, MA
Let’s Talk Compliance
24 January 2020
Orlando, FL
New England Alliance Annual Meeting
15-17 January 2020
Woodstock, VT